BFM
MXCT icon

Boothbay Fund Management’s MaxCyte MXCT Stock Holding History

Boothbay Fund Management’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,143
Closed -$92K – 2527
2022
Q1 		$92K Hold
13,143
– – ﹤0.01% 2115
2021
Q4 		$134K Sell
13,143
-2,022
-13% -$21.7K ﹤0.01% 1642
2021
Q3 		$185K Buy
+15,165
New +$229K 0.01% 1614

Other funds holding MXCT

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RGI
River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Boothbay Fund Management's MXCT Position: Q2 2022 in Review

Boothbay Fund Management sold out of MaxCyte (MXCT) in Q2 2022, closing a stake of 13,143 shares — an estimated $92K sold.

Boothbay Fund Management first reported a position in MXCT in Q3 2021 and held it in 3 quarters. The position peaked at $185K in Q3 2021. 102 funds tracked by Wall St. Rank hold MXCT as of Q2 2022.

  • Boothbay Fund Management reported no remaining MaxCyte position as of Q2 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 13,143 MaxCyte shares in Q2 2022, an estimated $92K.
  • Boothbay Fund Management first reported a position in MaxCyte in Q3 2021 and held it in 3 quarters.
  • Boothbay Fund Management's MaxCyte position peaked at $185K in Q3 2021.
  • 102 funds tracked by Wall St. Rank held MaxCyte as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.